GlassScriptPhysician profile
Jacob Craze
NPI 1558959403
$1,773.23
in general payments reported to CMS, 2019-2025
18 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $413 · 2022: $329 · 2023: $549 · 2024: $201 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $280.29 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $272.02 | 2021-2023 | Lupkynis |
| Novo Nordisk INC | $159.57 | 2022-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $158.65 | 2022-2023 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $136.99 | 2021-2023 | Veltassa, Korsuva |
| Ardelyx, INC. | $115.35 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $112.61 | 2025 | |
| Fresenius USA Marketing, INC. | $97.80 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $80.66 | 2024-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $65.67 | 2023-2024 | |
| Amgen INC. | $57.95 | 2021-2023 | Repatha |
| Akebia Therapeutics INC | $53.32 | 2021-2022 | |
| Glaxosmithkline, LLC. | $47.16 | 2021-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $39.69 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.81 | 2023-2024 | Xifaxan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.07 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $20.80 | 2023 | Verquvo |
| Calliditas Therapeutics US INC. | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Craze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.